Cite
HARVARD Citation
Colombel, J. et al. (n.d.). P573 The safety profile of upadacitinib maintenance therapy in ulcerative colitis in the Phase 3 U-ACHIEVE study is consistent with that in approved indications. Journal of Crohn's and colitis. p. i514. [Online].